Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project PharmaTimesQuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billionNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) PharmaTimes QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion Neuroscience Read full story Post navigation Previous: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot programNext: Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal Related Stories Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026